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A B S T R A C T   
A 3-months-old male domestic kitten was referred for repeated seizures. Analysis revealed Cryptococcus neo-
formans. Levetiracetam and fluconazole were administered without significant clinical improvements and 
without negativization. Hypothesizing resistance, therapy was switched to amphotericin B. Seizure disappeared. 
Haematological controls highlighted transitory increasing of CK, BUN, ALP and cholesterol. PCR repeated two 
weeks after the treatment was negative for Cryptococcus neoformans. Nowadays the cat is 5 years old, and no 
seizures occurred since the age of 5 months.   
1. Introduction 
Cryptococcosis is a non-contagious systemic fungal disease, occur-
ring worldwide and is observed more commonly in cats than in dogs [1]. 
The etiological agent is Cryptococcus neoformans, an airborne pathogen, 
and cats might acquire the infection by inhalating basidiospores in a 
contaminated environment. The incubation period is variable and when 
the invasion of nasal mucosal layer occurs, disease develops locally 
and/or systemically, from the upper respiratory tract to the central 
nervous system (CNS) [2,3]. CNS involvement becomes clinically 
evident with sudden blindness due to optical neuritis, seizures, or 
behavioral changes due to the development of granulomatous 
encephalo-myelitis with solitary or multiple lesions and it is usually 
associated with poor therapy response and survival outcome [4,5]. 
To diagnose Cryptococcus neoformans, it is possible to perform 
cytology, histology, antibody detection and culture, but the most reli-
able test is PCR. Advanced diagnostic imaging techniques (i.e. MRI) are 
recommended to investigate CNS lesions in case of symptomatic patients 
[1]. 
The prognosis is favorable in most cases if the diagnosis is made early 
(before dissemination or prior to development of irreversible lesions) 
and patients and owners comply with a long course of treatment 
(months) and follow-up (years) [5]. 
According to the literature, it is not possible to determine a 
predisposition of age and breed, even if it has been reported that 
Cryptococcosis is more frequently diagnosed in adults [6]. 
Considering all the aforementioned factors, the present case report 
should be worthy of reader’s attention due to the fact it deals with the 
diagnostic and therapeutic process of a very young subject with a pos-
itive PCR for Cryptococcus neoformans, presenting critical CNS symptoms 
and that was unresponsive to first line specific treatment for 
Cryptococcosis. 
2. Case 
During winter 2015, a 2-month male owned kitten was referred to 
veterinarians for repeated seizure. Owners declared that the kitten was 
maintained in a household environment, that no trauma occurred, and 
that seizure started few days after adoption from a stray cat recovery 
association. According to the instruction given by the Veterinarian of the 
association, a first therapeutic attempt was tried to control seizure by 
oral (PO) administration of phenobarbital (2.5 mg q12h). The therapy 
was maintained for more than one month, without appreciable 
improvement. 
At the age of 3-months, the kitten was referred for consultation to 
other Veterinarians (considered day 0). The general clinical examination 
was normal, except for a very low body condition score (BCS=1, the cat 
weighted 900grams), bristling hairs and depression. Owners showed 
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several videos of seizure episodes. Several differentials were considered, 
mostly related to infectious etiologies and central nervous system mal-
formation (i.e.: hydrocephalous). The kitten was presented few days 
later to a Veterinary Hospital for a further diagnostic work-up. Blood 
samples were collected to perform blood cell count and biochemistry. 
BCC was within the physiological range while among biochemical pa-
rameters the creatin phosphokinase (CK) was increased (626 U/L). 
Blood aliquots were also used for Toxoplasma gondii IgG/IgM detection, 
and Cryptococcus neoformans identification using real time PCR tech-
nique. For template DNA preparation, a blood sample was processed 
with the QIAamp tissue kit (Qiagen, Hilden, Germany) according to the 
manufacturer’s instructions. The real time PCR was performed with 
oligonucleotide primers: Cryn-F and Cryn-R (5’ GTTAAAAAGCTCG-
TAGTTG 3’ and 5’ TCCCTAGTCGGCATAGTTTA 3’) complementary to 
highly conserved regions within the nuclear gene coding for a small 
subunit of rRNA (18S rDNA) of C. neoformans and generate a 429-bp 
amplicon [7]. Amplification was performed in a StepOne™ Real-Time 
PCR System (Applied Byosistems, ThermoFisher, UK). 
A complete neurological examination and an MRI in presence of a 
paramagnetic intravenous marker were performed by a specialist. 
Hyperintensity in olfactory lobes, nostrils and olfactory sinus was 
highlighted in SeT2 sequences with moderate enhancement after the 
marker administration. An ophthalmologic exam revealed the presence 
of pathognomonic chorionic lesions attributable to cryptococcosis. 
Given the severity and the frequency of seizure, levetiracetam was 
initiated at 20 mg/kg PO q8h. Real time PCR demonstrated the positivity 
for C. neoformans. According to this finding, blood sample and nasal 
swabs were seeded in specific culture media to isolate C. neoformans and 
fluconazole was initiated at 10 mg/kg PO q12h. Culture results were 
negative. Hematological controls were performed every 15 days. Several 
days (33) after the beginning of the therapy, seizures began once again, 
becoming more and more frequent in the further two weeks. PCR was 
repeated and demonstrated a persistent positivity. Veterinarians hy-
pothesized a lack of efficacy of fluconazole and decided to hospitalize 
the patient. Seizures were treated by administering benzodiazepines 
rectally and it was chosen to administer amphotericin B at the dose of 1 
mg/kg, q48h for three consecutive times. Fluid therapy was constantly 
maintained, and blood biochemistry was checked daily to evaluate 
possible renal toxicity. Seizure disappeared at the end of the adminis-
tration protocol and the kitten was discharged. Following hematological 
controls highlighted a transitory increasing of creatine kinase, BUN, 
alkaline phosphatase, and cholesterol. The clinical examination was 
good, and the PCR repeated two weeks after the end of the treatment 
was negative for C. neoformans. 
Nowadays the cat is 5 years old, and seizures disappeared at the age 
of 5 months. 
3. Discussion 
This is the first case report describing a possible drug resistance 
phenomenon in a 3 months-old kitten affected by C. neoformans with 
good outcome even with a critical involvement of CNS. 
No prospective controlled studies exist on the treatment of feline 
cryptococcosis, and all data are based on retrospective studies and case 
reports. Treatment guidelines have been delineated and the choice of 
appropriate antifungal drug depends on many factors.1 Differences in 
the susceptibility of the various Cryptococcus spp. and genotypes to 
antimycotic drugs, in general and against fluconazole (FCZ) in partic-
ular, have been reported [6]. Consequently, the molecular identification 
of the isolates is important in defining the treatment protocol. Moreover, 
isolates with different geographical origins may show different suscep-
tibilities [8]. According to these considerations, some drugs are 
considered as a milestone in Cryptococcosis therapy, but information for 
paediatric subjects is anecdotical. 
Azoles encompass fungistatic drugs, that can inhibit the synthesis of 
ergosterol, a primary component of fungal membranes [9]. Fluconazole 
seems to be more effective than itraconazole for infections involving the 
CNS, eye, and urinary tract, and is also better tolerated.4 Fluconazole 
and itraconazole are both less toxic and present better therapeutic and 
pharmacodynamic/pharmacokinetic characteristics than ketoconazole. 
The most significant advantage of fluconazole is its ability (shared 
neither with ketoconazole nor itraconazole) to pass the blood-brain 
barrier and the blood-ocular barrier, thus making it suitable to treat 
mycotic infections of these organs. Side effects of fluconazole may 
include gastrointestinal disturbances and hepatotoxicity and it is 
considered teratogenic [10]. Fluconazole should be administered in 
adults at the dose of 50 mg PO q12h, for 1- 2 months after the resolution 
of clinical signs [11]. Itraconazole may be used in kittens at the dose of 5 
to 10 mg/kg q24h [12]. 
Amphotericin B is an old polyene antimycotic drug, fungistatic or 
fungicidal, depending on concentration [13]. It acts by binding sterols in 
the cell membrane and altering the permeability [11]. Alone or in 
combination with 5-flucytosine it may be the first choice or can be the 
right alternative after a first treatment with fluconazole or itraconazole.4 
It is not well absorbed by oral route, thus it must be administrated 
intravenously (IV), with subsequent problems in restrained patients. 
Novel approaches aimed at improving the oral availability of ampho-
tericin B by using various excipients have been published [14]. Side 
effects are mainly represented by nephrotoxicity. To avoid this effect, 
liposomal preparations have been developed, with a lipid complex and a 
colloidal dispersion in cholesterol sulphate. Although significantly less 
toxic, these preparations are more expensive, thus limiting the use in 
veterinary medicine. Consequently, they are used mostly in cases in 
which other drugs fail [15]. Doses varies according to the diagnosis and 
the formulation. 
In the present case, Veterinarians decided not to administer gluco-
corticoids even if this class of drugs is suggested to be used in adult cats 
affected by this pathology [12]. Glucocorticoids should be considered if 
signs of brain oedema are present or in case of significant neurologic 
deterioration in MRI. Dexamethasone sodium phosphate 0.1 mg/kg IV 
or subcutaneously q12h followed by prednisone 0.5 mg/kg PO q12h is 
used. Prednisone should be tapered over 1 to 2 weeks if possible, to 
avoid immunosuppression especially in young subjects [12]. 
The clinical course of the kitten presented in this case report, could 
indicate a resistance to azoles: C. neoformans resistance to azole com-
pounds has been frequently reported in humans presenting AIDS [16]. 
Relating to veterinary medicine, the molecular mechanisms behind 
azoles resistance in C. neoformans have been demonstrated in the 
increased expression of ERG11 and efflux pumps [17]. Moreover, Kano 
and colleagues reported an in vitro resistance to fluconazole in a 
C. neoformans var. grubii from a cat but the microorganisms remained 
susceptible to amphotericin B and itraconazole [18]. These results are in 
accordance with Lester and co-workers who reported resistance to flu-
conazole in some C. neoformans isolates that remain susceptible to other 
azoles [19]. It is important to underline that all information related to 
amphotericin effects and azole resistance are all related to adult subjects 
and that it is necessary to collect specific data about pediatric ones due 
to the fact that drug disposition, distribution, metabolism and excretion 
are extremely different between the two aforementioned categories of 
patients. Till the age of 6 months, puppies and kittens have a higher 
percentage of body water than adults, demonstrating a variable binding 
of the drug with plasma proteins, showing a deficiency of phase I and II 
enzymes and a reduced renal excretion [20]. According to this, it is 
correct to hypothesize the administration of lower doses and to prolong 
intervals of administration to avoid side effects but, it has to be 
considered also a poor therapeutic response that may result from the 
limited administration. 
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